Domenico Magazzù

2.1k citations

18 papers · 1.4k indexed · 1 hit paper · h-index 12

Cancer Research top 5%
- Breast Cancer Treatment Studies 6
- Cancer Genomics and Diagnostics 3
Oncology top 5%
- Cancer Treatment and Pharmacology 4
- HER2/EGFR in Cancer Research 4
- Cancer Immunotherapy and Biomarkers 2
Hepatology top 10%
Radiology, Nuclear Medicine and Imaging top 5%
Safety, Risk, Reliability and Quality top 5%
Surgery
- Testicular diseases and treatments 2
Genetics
- Chronic Lymphocytic Leukemia Research 2
Hematology
- Multiple Myeloma Research and Treatments 2

Co-authors: Pinuccia Valagussa Semiglazov Vf Aňa Lluch Luca Gianni Juan de la Haba-Rodríguez Young‐Hyuck Im Tadeusz Pieńkowski Ling‐Ming Tseng
Cited by: Cancer Research Oncology Hepatology
Partner nations: Italy Spain Russia

In The Last Decade

Domenico Magazzù

18 papers receiving 1.3k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2016 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial

Peers

Countries citing papers authored by Domenico Magazzù

Since Specialization

Citations

This map shows the geographic impact of Domenico Magazzù's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Domenico Magazzù with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Domenico Magazzù more than expected).

Fields of papers citing papers by Domenico Magazzù

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Domenico Magazzù. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Domenico Magazzù. The network helps show where Domenico Magazzù may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Domenico Magazzù, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Domenico Magazzù Line = papers co-authored together Domenico Magazzù links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work
1	Phase 1b dose-finding study of avelumab (anti-PD-L1) + axitinib in treatment-naïve patients with advanced renal cell carcinoma James Larkin,Brian I. Rini,Paul Nathan,Fiona Thistlethwaite,Michael S. Gordon,M. Martgnoni,Domenico Magazzù,C. Chiruzzi,Alessandra di Pietro,Toni K. Choueiri	2016	12
2	Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy Failure Andrea Necchi,Andrea Anichini,Daniele Raggi,Patrizia Giannatempo,Domenico Magazzù,Nicola Nicolai,Maurizio Colecchia,Biagio Paolini,Elisa Coradeschi,Elena Tassi,Giulia Grazia,Roberta Mortarini,Giuseppina Calareso,Raffaella De Fato,E. Togliardi,Flavio Crippa,Roberto Salvioni,Pinuccia Valagussa,Alessandro M. Gianni	2016	25
3	5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trialbreakdown → Luca Gianni,Tadeusz Pieńkowski,Young‐Hyuck Im,Ling‐Ming Tseng,Mei-Ching Liu,Aňa Lluch,Elżbieta Starosławska,Juan de la Haba-Rodríguez,Seock‐Ah Im,José Luiz Pedrini,Brigitte Poirier,Paolo Morandi,Semiglazov Vf,Vichien Srimuninnimit,Giulia Bianchi,Domenico Magazzù,Virginia McNally,Hannah Douthwaite,Graham Ross,Pinuccia Valagussa	2016	555
4	An open-label, single-group, phase 2 study of brentuximab vedotin as salvage therapy for males with relapsed germ-cell tumors (GCT): Results at the end of first stage (FM12GCT01). Andrea Necchi,Domenico Magazzù,Andrea Anichini,Daniele Raggi,Patrizia Giannatempo,Nicola Nicolai,Maurizio Colecchia,Biagio Paolini,Elisa Coradeschi,Elena Tassi,Giulia Grazia,Roberta Mortarini,Giuseppina Calareso,E. Togliardi,Flavio Crippa,Roberto Salvioni,Alessandro M. Gianni,Pinuccia Valagussa	2016	15
5	ETNA (Evaluating Treatment with Neoadjuvant Abraxane) randomized phase III study comparing neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) both followed by anthracycline regimens in women with HER2-negative high-risk breast cancer: A MICHELANGO study. Luca Gianni,Mauro Mansutti,Antonio Antón,Lourdes Calvo,Giancarlo Bisagni,Begoña Bermejo,Semiglazov Vf,Marc Thill,José Ignacio Chacón,Arlene Chan,Serafín Morales,Isabel Álvarez,Arrate Plazaola,Milvia Zambetti,Andrew Redfern,Christian Dittrich,Rebecca Dent,Domenico Magazzù,Pinuccia Valagussa,Ignacio Tusquets	2016	11
6	Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial Giampaolo Bianchini,Lajos Pusztai,Tadeusz Pieńkowski,Young‐Hyuck Im,Giulia Bianchi,Ling‐Ming Tseng,M.-C. Liu,Aňa Lluch,Eugenia Galeota,Domenico Magazzù,Juan de la Haba-Rodríguez,Do‐Youn Oh,Brigitte Poirier,José Luiz Pedrini,Semiglazov Vf,Pinuccia Valagussa,Luca Gianni	2015	95
7	Management of breast cancer after Hodgkin’s lymphoma and paediatric cancer Monica Terenziani,Maura Massimino,Domenico Magazzù,Lorenza Gandola,Giuseppe Capri,Maria Luisa Carcangiu,S Catania,Anna Russo,Massimiliano Gennaro,Cristina Meazza,Marta Podda,Elisabetta Schiavello,Pinuccia Valagussa	2015	5
8	Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort Luca Gianni,W. Eiermann,Semiglazov Vf,Aňa Lluch,Sergei Tjulandin,Milvia Zambetti,Angela Moliterni,Federico Vázquez,M. Byakhov,Mikhail Lichinitser,Miguel Ángel Climent,Eva Ciruelos,B. Ojeda,Mauro Mansutti,А. А. Божок,Domenico Magazzù,Dominik Heinzmann,Jutta Steinseifer,Pinuccia Valagussa,José Baselga	2014	356
9	Proliferation-, estrogen-, and T-cell-related metagenes to predict outcome after adjuvant/neoadjuvant chemotherapy for operable breast cancer in the ECTO trial. Giampaolo Bianchini,Vera Cappelletti,Maurizio Callari,Maria Luisa Carcangiu,W. Eiermann,Semiglazov Vf,Vicente Guillém,Aňa Lluch,Mauro Mansutti,Milvia Zambetti,Gabriella Mariani,Domenico Magazzù,Pinuccia Valagussa,Biagio Paolini,Valeria Musella,Eleonora Di Buduo,Patrizia Miodini,Manuela Scuro,Maria Grazia Daidone,Luca Gianni	2013	3
10	Follow-up results of NOAH, a randomized phase III trial evaluating neoadjuvant chemotherapy with trastuzumab (CT+H) followed by adjuvant H versus CT alone, in patients with HER2-positive locally advanced breast cancer. Luca Gianni,W. Eiermann,Semiglazov Vf,Alexey Manikhas,Aňa Lluch,Sergei Tjulandin,Milvia Zambetti,Federico Vázquez,M. Byakhov,Mikhail Lichinitser,Miguel Ángel Climent,Eva Ciruelos,B. Ojeda,Mauro Mansutti,А. А. Божок,Domenico Magazzù,Jutta Steinseifer,Pinuccia Valagussa,José Baselga	2013	11
11	Freedom from progression (FFP) by adding paclitaxel (T) to doxorubicin (A) followed by CMF as adjuvant or primary systemic therapy: 10-yr results of a randomized phase III European Cooperative Trial in Operable Breast Cancer (ECTO). Milvia Zambetti,José Baselga,W. Eiermann,Vicente Guillém,Semiglazov Vf,Aňa Lluch,Dolores Sabadell,А. А. Божок,M. Byakhov,B. Ojeda,Mauro Mansutti,Gabriella Mariani,Angela Moliterni,H. Cortés-Funes,Marian Colozza,Tadeusz Pieńkowski,Domenico Magazzù,Pinuccia Valagussa,Gianni Bonadonna,Luca Gianni	2013	1
12	A Phase IIIb Multicentre Open-Label Study of Nilotinib in Adult Patients with Newly Diagnosed BCR-ABL Positive Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A European Clinical Initiative with EUTOS Collaboration for Standardisation of Molecular Remission Francis J. Giles,Gianantonio Rosti,Gert J. Ossenkoppele,Michel Tulliez,Jesper Stentoft,Aristoteles Giagounidis,Francesco Nobile,Philipp D. le Coutre,Norbert Gattermann,Laimonas Griškevičius,Nicholas C.P. Cross,Sarah J. Hill,Peter Schuld,Angela Maria Pellegrino,Domenico Magazzù,Andreas Hochhaus	2011	2
13	Mild hyperhomocysteinemia, C677T polymorphism on methylenetetrahydrofolate reductase gene and the risk of macroangiopathy in type 2 diabetes: a prospective study Giuseppina Russo,A. Di Benedetto,Domenico Magazzù,Annalisa Giandalia,Carlo Giorda,Riccardo Ientile,M. Previti,E. Di Cesare,Domenico Cucinotta	2009	24
14	Borderline sweat test: Utility and limits of genetic analysis for the diagnosis of cystic fibrosis Manuela Seia,Lucy Costantino,Valentina Paracchini,Luigi Porcaro,P. Capasso,Domenico Coviello,Carlo Corbetta,Erminio Torresani,Domenico Magazzù,Vincenza Consalvo,Andrea Siqueira Campos Monti,Diana Costantini,Carla Colombo	2009	11
15	Diagnosis on a positive fashion of nonorganic failure to thrive Fabio Panetta,Domenico Magazzù,Concetta Sferlazzas,Mariangela Lombardo,Giuseppe Magazzù,Maria Cristina Lucanto	2008	4
16	Phase I study of the pan aurora kinases (AKs) inhibitor PHA-739358 administered as a 24 h infusion without/with G-CSF in a 14-day cycle in patients with advanced solid tumors Richard B. Cohen,Suzanne F. Jones,Margaret von Mehren,Jie Cheng,Don Spiegel,B. Laffranchi,Mariangela Mariani,R. Spinelli,Domenico Magazzù,H. A. Burris	2008	11
17	Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients Giovanni Squadrito,Teresa Pollicino,Irene Cacciola,Gaia Caccamo,Daniela Villari,Tiziana La Masa,Tea Restuccia,Eugenio Cucinotta,Claudio Scisca,Domenico Magazzù,Giovanni Raimondo	2006	118
18	Are car drivers holding a motorcycle licence less responsible for motorcycle—Car crash occurrence? Domenico Magazzù,Mario Comelli,Alessandra Marinoni	2005	92

About Domenico Magazzù

Domenico Magazzù is a scholar working on Cancer Research, Hematology and Oncology, having authored 18 papers that have together received 1.4k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (6 papers), Cancer Treatment and Pharmacology (4 papers), HER2/EGFR in Cancer Research (4 papers), Cancer Genomics and Diagnostics (3 papers), Testicular diseases and treatments (2 papers), Chronic Lymphocytic Leukemia Research (2 papers), Multiple Myeloma Research and Treatments (2 papers) and Cancer Immunotherapy and Biomarkers (2 papers). The work is most often cited by research in Cancer Research (570 citations), Oncology (905 citations) and Hepatology (112 citations). Domenico Magazzù has collaborated with scholars based in Italy, Spain and Russia. Frequent co-authors include Pinuccia Valagussa, Semiglazov Vf, Aňa Lluch, Luca Gianni, Juan de la Haba-Rodríguez, Young‐Hyuck Im, Tadeusz Pieńkowski, Ling‐Ming Tseng, Brigitte Poirier and José Luiz Pedrini.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact